sefulness of a novel biomarker procalcitonin to guide antibiotic therapy in children with chest infections
Not Applicable
Completed
- Conditions
- Paediatric lower respiratory tract infectionsInfections and Infestations
- Registration Number
- ISRCTN17057980
- Lead Sponsor
- niversity Children's Hospital Basel (Switzerland)
- Brief Summary
2013 results in https://pubmed.ncbi.nlm.nih.gov/23936304/ (added 30/12/2020)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 337
Inclusion Criteria
1. Both males and females, 1 month to 18 years of age
2. Two pre-specified sub-groups will be recruited:
2.1. Patients with acute LRTI based on clinical diagnosis
2.2. Patients with X-ray confirmed community acquired pneumonia (CAP)
Exclusion Criteria
1. Patients who have been hospitalised within the previous 14 days
2. Patients with immune-suppression, chronic infection, or a terminal condition
3. Patients lacking informed consent
4. Insufficient knowledge of German (in a family member)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Antibiotic prescription rate at Day 1, 3, 5 and 14.
- Secondary Outcome Measures
Name Time Method <br> 1. Time to recovery (days with restriction from LRTI)<br> 2. Rate and duration of hospitalisation<br> 3. Complication rate<br> 4. Measures of laboratory and clinical outcome<br> 5. Side effects from AB<br> 6. Disease activity scores<br><br> Endpoints will be assessed at day 1, 3 and 5 in the form of a medical consultation at the hospital, and after 14 days by structured phone interviews conducted by blinded investigators.<br>